In recent trading session, Astrazeneca plc ADR (NASDAQ:AZN) saw 1.11 million shares changing hands at last check today with its beta currently measuring 0.36. Company’s recent per share price level of $69.32 trading at -$0.76 or -1.09% at last check today assigns it a market valuation of $214.97B. That most recent trading price of AZN’s stock is at a discount of -26.49% from its 52-week high price of $87.68 and is indicating a premium of 11.66% from its 52-week low price of $61.24. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.32 million shares which gives us an average trading volume of 4.52 million if we extend that period to 3-months.
For Astrazeneca plc ADR (AZN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.37. Splitting up the data highlights that, out of 10 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 8 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Astrazeneca plc ADR (NASDAQ:AZN) trade information
Upright in the red during last session for losing -1.09%, in the last five days AZN remained trading in the red while hitting it’s week-highest on Monday, 07/14/25 when the stock touched $69.32 price level, adding 4.0% to its value on the day. Astrazeneca plc ADR’s shares saw a change of -11.27% in year-to-date performance and have moved -3.47% in past 5-day. Astrazeneca plc ADR (NASDAQ:AZN) showed a performance of -5.76% in past 30-days. Number of shares sold short was 7.45 million shares which calculate 1.73 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 97 to the stock, which implies a rise of 28.54% to its recent value today. Analysts have been projecting 97 as a low price target for the stock while placing it at a high target of 97. It follows that stock’s current price would drop -39.93% in reaching the projected high whereas dropping to the targeted low would mean a loss of -39.93% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 34.63% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 10.05% while estimates for its earnings growth in next 5 years are of 11.46%.
AZN Dividends
Astrazeneca plc ADR is more likely to be releasing its next quarterly report on 2025-Apr-29 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt. With an annual yield of 2.24%, the share has a forward dividend of 1.55 which implies that company’s dividend yield remained growing in trailing twelve months while having a 5 year average dividend yield of 2.26%.
Astrazeneca plc ADR (NASDAQ:AZN)’s Major holders
Insiders are in possession of 0.00% of company’s total shares while institution are holding 17.08 percent of that, with stock having share float percentage of 17.08%. Investors also watch the number of corporate investors in a company very closely, which is 17.08% institutions for Astrazeneca plc ADR that are currently holding shares of the company. PRICE T ROWE ASSOCIATES INC /MD/ is the top institutional holder at AZN for having 64.94 million shares of worth $5.06 billion. And as of 2024-06-30, it was holding 4.1788 of the company’s outstanding shares.
The second largest institutional holder is PRIMECAP MANAGEMENT CO/CA/, which was holding about 42.6 million shares on 2024-06-30. The number of shares represents firm’s hold over 2.7411 of outstanding shares, having a total worth of $3.32 billion.
On the other hand, VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund and WASHINGTON MUTUAL INVESTORS FUND are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 25.51 shares of worth $1.77 billion or 0.97% of the total outstanding shares. The later fund manager was in possession of 20.06 shares on Apr 30, 2025 , making its stake of worth around $1.39 billion in the company or a holder of 0.76% of company’s stock.
